Breakthrough in Parkinson's Research: Unraveling the Synergy of Disease-Linked Proteins' Structures - written by Harsha varthini.B (Managing Editor, Bisjhintus News)

This groundbreaking study delves into  the intricate structures of two Parkinson's disease-related proteins, shedding light on their interplay and potential implications for drug design.

Key Points:

1. Complex Structure Revelation:

Scientists at St. Jude Children's Research Hospital unveil the complex structures of two Parkinson's disease-related proteins: Leucine-rich repeat kinase 2 (LRRK2) and Rab29.

LRRK2, a protein kinase modifying other proteins through phosphorylation, and Rab29, a regulator of cellular trafficking, work together in late-onset Parkinson's cases.

2. Understanding Synergistic Mechanisms:

Despite being implicated in Parkinson's, the exact synergy between Rab29 and LRRK2 remains unclear.

Researchers, led by Dr. Ji Sun, utilized cryo-electron microscopy to determine the structures of LRRK2 bound to Rab29, offering insights into LRRK2 regulation and potential drug design implications.

3. Parkinson's Disease Background:

Parkinson's disease, the second-most common neurodegenerative disease, affects 1-2% of the population over 65.

Approximately 15% of cases have a genetic link, with LRRK2 mutation being a common cause.

4. Challenges in Studying LRRK2:

LRRK2's large size made structural studies challenging.

 In 2021, the team presented the first structure of full-length LRRK2, revealing its inactive conformation.

5. Search for Active Conformation:

Researchers aimed to find LRRK2's active conformation, requiring careful exploration due to LRRK2's ability to form oligomers.

Cryo-electron microscopy revealed structures of the Rab29-LRRK2 complex, including unexpected tetramers representing the active conformation.

6. Activation by Spatial Arrangement:

LRRK2's activation is influenced not only by interacting proteins but also by their spatial arrangement within cells.

The transition from monomer to tetramer is facilitated when Rab29 recruits LRRK2 to the membrane, increasing local concentration.

7. Implications for Parkinson's Treatment:

The atomic-scale map provided by these structures helps trace how mutations affecting LRRK2 cause Parkinson's disease.

Insights gained offer potential applications for drug design, including the validation of findings with the drug DNL201, which locks LRRK2 in an active state.

8. Medicinal Chemistry Insights:

The study's structures, showcasing inactive and active conformations, provide valuable insights for medicinal chemists to design novel inhibitors against LRRK2 for Parkinson's treatment.

This research marks a significant step forward in understanding the molecular intricacies of Parkinson's disease, offering a foundation for targeted drug development and potential breakthroughs in treatment strategies.